Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States

被引：26

作者：

Grant, Linda Ahdieh ^{[1
]}

Dunne, Eileen F. ^{[1
]}

Chesson, Harrell ^{[1
]}

Markowitz, Lauri E. ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA

来源：

VACCINE | 2011年 / 29卷 / 13期

关键词：

HPV vaccine; Mid adult women; Older women; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-EFFECTIVENESS; NATURAL-HISTORY; RISK-FACTORS; INFECTION; HEALTH; PERSISTENCE; DURATION; GUANACASTE; COHORT;

D O I：

10.1016/j.vaccine.2011.01.032

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In the United States, human papillomavirus (HPV) vaccination is recommended for 11 or 12 year old girls, with catch-up vaccination through age 26 years. Data are available for women over the age of 26 years on immunogenicity for both quadrivalent and bivalent HPV vaccines and on efficacy for the quadrivalent HPV vaccine. If HPV vaccines are licensed for use in women over 26 years of age (mid-adult women), recommendations for this age group will need to be considered. This review summarizes vaccine efficacy and immunogenicity data in mid-adult women, and addresses epidemiologic data related to key questions for consideration of vaccine recommendations for women over age 26 years. Published by Elsevier Ltd.

引用

页码：2365 / 2370

页数：6

共 48 条

[1]

Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P626

[2] Literature review of human papillomavirus vaccine acceptability among women over 26 years [J].

Black, Lora L. ;

Zimet, Gregory D. ;

Short, Mary B. ;

Sturm, Lynne ;

Rosenthal, Susan L. .

VACCINE, 2009, 27 (11) :1668-1673

[3]

Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3

[4] Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].

Carter, JJ ;

Koutsky, LA ;

Hughes, JP ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919

[5] A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica [J].

Castle, PE ;

Schiffman, M ;

Herrero, R ;

Hildesheim, A ;

Rodriguez, AC ;

Bratti, MC ;

Sherman, ME ;

Wacholder, S ;

Tarone, R ;

Burk, RD .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) :1808-1816

[6] Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection [J].

Cecilia Rodriguez, Ana ;

Schiffman, Mark ;

Herrero, Rolando ;

Hildesheim, Allan ;

Bratti, Concepcion ;

Sherman, Mark E. ;

Solomon, Diane ;

Guillen, Diego ;

Alfaro, Mario ;

Morales, Jorge ;

Hutchinson, Martha ;

Katki, Hormuzd ;

Cheung, Li ;

Wacholder, Sholom ;

Burk, Robert D. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (05) :315-324

[7] Cost-effectiveness of human papillomavirus vaccination in the United States [J].

Chesson, Harrell W. ;

Ekwueme, Donatus U. ;

Saraiya, Mona ;

Markowitz, Lauri E. .

EMERGING INFECTIOUS DISEASES, 2008, 14 (02) :244-251

[8]

DASBACH EJ, 2008, INF DIS SOC OBST GYN

[9]

Dempsey Amanda F, 2008, Rev Obstet Gynecol, V1, P122

[10] Prevalence of HPV infection among females in the United States [J].

Dunne, Eileen F. ;

Unger, Elizabeth R. ;

Sternberg, Maya ;

McQuillan, Geraldine ;

Swan, David C. ;

Patel, Sonya S. ;

Markowitz, Lauri E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (08) :813-819

← 1 2 3 4 5 →